Search Results - "Göynük, Büsra"

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors by Middelburg, Jim, Sluijter, Marjolein, Schaap, Gaby, Göynük, Büşra, Lloyd, Katy, Ovcinnikovs, Vitalijs, Zom, Gijs G., Marijnissen, Renoud J., Groeneveldt, Christianne, Griffioen, Lisa, Sandker, Gerwin G. W., Heskamp, Sandra, van der Burg, Sjoerd H., Arakelian, Tsolere, Ossendorp, Ferry, Arens, Ramon, Schuurman, Janine, Kemper, Kristel, van Hall, Thorbald

“…CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so…”
Get full text

The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent by Middelburg, Jim, Ghaffari, Soroush, Schoufour, Tom A.W., Sluijter, Marjolein, Schaap, Gaby, Göynük, Büsra, Sala, Benedetta M., Al-Tamimi, Lejla, Scheeren, Ferenc, Franken, Kees L.M.C., Akkermans, Jimmy J.L.L., Cabukusta, Birol, Joosten, Simone A., Derksen, Ian, Neefjes, Jacques, van der Burg, Sjoerd H., Achour, Adnane, Wijdeven, Ruud H.M., Weidanz, Jon, van Hall, Thorbald

“…The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently…”
Get full text

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI by Broeders, Mike, Smits, Kasper, Goynuk, Busra, Oussoren, Esmee, van den Hout, Hannerieke J.M.P., Bergsma, Atze J., van der Ploeg, Ans T., Pijnappel, W.W.M. Pim

“…Identification and characterization of disease-associated variants in monogenic disorders is an important aspect of diagnosis, genetic counseling, prediction…”
Get full text